Second Line Therapy Decision Factors

A key opinion leader discusses the

For more resources and information regarding anticancer targeted

Martin H. Voss, MD, highlights the

John L. Marshall, MD; Johanna C. Bendell, MD; Cathy Eng, MD, FACP; Dale R. Shepard, MD, PhD, FACP; and Michael A. Morse, ...

Thomas E. Hutson, DO, PharmD; Nizar M. Tannir, MD, FACP; and Chung-Han Lee, MD, PhD, discuss practical implications for ...

Benjamin P. Levy, MD, reviews the options for

Triggers that should alert clinicians to initiate

Bhuvana Sagar, MD, discusses access issues around

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, a roundtable of expert panelists convened ...

Wells Messersmith, MD, reviews the case of the 66-year-old male patient with progression of metastatic colorectal cancer and ...

With

When first-

Panelists Robert A. Figlin, MD, and David I. Quinn, MBBS, PhD, provide insight on

... supporting

Whilst enfortumab vedotin and pembrolizumab have been established as the first-

Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, discusses the

A review of a phase 3 trial on cabozantinib as well as the use of regorafenib and ramucirumab as seen in the RESORCE and ...

Key opinion leaders consider the

Edward Chu, MD, provides insight on the

M1 CRPC: First and